fda compounding semaglutide warning 2025 october New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA is moving to restrict

These states include Hawaii (0.4%), Arizona (0.5%), Colorado (0.6%), Nevada (0.6%), New Mexico (0.6%), Oregon (0.6%), Washington (0.7%), and Utah (0.7%)

The use of supplements of like acetyl-L-carnitine or omega 3 fatty acids is not a replacement for proper treatment from a licensed medical professional

Eradicates scars and marks caused by pimples and acne

Current Access Options for BPC-157 While BPC-157 transitions through the regulatory process, patients may have several options depending on their location and healthcare provider: 503A compounding pharmacies: Some state-licensed pharmacies may still compound BPC-157 depending on their state's regulations and interpretation of the current federal guidance

How is this stuff actually made